Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-27T13:03:47.943Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term atorvastatin–ezetimibe–probucol triple therapy for homozygous familial hypercholesterolaemia from early childhood

Published online by Cambridge University Press:  24 April 2015

Minjie Lin ,
Helong Dai  and
Shuiping Zhao
Minjie Lin
Affiliation:
Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, PR China
Helong Dai
Affiliation:
Department of Urological Organ Transplantation, Center of Organ Transplantation, Second Xiangya Hospital, Central South University, Changsha, PR China
Shuiping Zhao*
Affiliation:
Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, PR China
*
Correspondence to: S. Zhao, PhD, Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha 410011, PR China. Tel: +860 731 8529 5806; Fax: +8 607 318 536 0309; E-mail: zhaosp2014@163.com
Get access Rights & Permissions [Opens in a new window]

Abstract

In this observational case report, we share our experience of achieving >40% LDL cholesterol reduction in four Chinese homozygous familial hypercholesterolaemia children below 8 years of age with a triple combination of atorvastatin, probucol, and ezetimibe for >6 years. Within a follow-up duration of 6–13 years, this triple therapy achieved significant reduction of LDL cholesterol as well as an impressive regression of xanthomas in all paediatric cases. All the children remained free from treatment-related adverse responses and cardiovascular events throughout follow-up.

Keywords

Homozygous familial hypercholesterolaemiaLDL cholesterolatherosclerotic cardiovascular diseasexanthoma
Type
Brief Reports
Information
Cardiology in the Young , Volume 26 , Supplement 1 , January 2016 , pp. 197 - 201
Check for updates
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Cuchel, M, Bruckert, E, Ginsberg, HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35: 2146–2157.Google Scholar
2. Soutar, AK, Naoumova, RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4: 214–225.Google Scholar
3. Nordestgaard, BG, Chapman, MJ, Humphries, SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478–3490.Google Scholar
4. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 (Suppl 5): S213–S256.Google Scholar
5. Goldstein, JL, Hobbs, HH, Brown, MS. The Metabolic and Molecular Bases of Inherited Disease. Familial Hypercholesterolemia. New York: McGraw-Hill; 2001, 2863–2913.Google Scholar
6. Rader, DJ, Cohen, J, Hobbs, HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111: 1795–1803.Google Scholar
7. Umans-Eckenhausen, MA, Defesche, JC, Sijbrands, EJ, Scheerder, RL, Kastelein, JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357: 165–168.Google Scholar
8. Naoumova, RP, Thompson, GR, Soutar, AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004; 15: 413–422.Google Scholar
9. Moriarty, PM. LDL-apheresis therapy. Curr Treat Options Cardiovasc Med 2006; 8: 282–288.Google Scholar
10. Moini, M, Mistry, P, Schilsky, ML. Liver transplantation for inherited metabolic disorders of the liver. Curr Opin Organ Transplant 2010; 15: 269–276.Google Scholar
Supplementary material: File

Lin supplementary material

Tables S1-S4

Download Lin supplementary material(File)
File 23.1 KB